drugset / Trial / NCT07193134

GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

NCT07193134 ↗

Phase 1/2 Recruiting 9 enrolled CHU de Quebec-Universite Laval
NaSingle-groupOpen-labelTreatment

Summary

This study is being done to find out if a new type of skin graft, called GMEB-SASS, is safe and effective for helping wounds heal in people with RDEB (Recessive Dystrophic Epidermolysis Bullosa). The GMEB-SASS graft contains two types of living skin cells: keratinocytes and fibroblasts. It is made in a laboratory using a small sample of the patient's own skin. To help the patient's skin cells produce a missing protein called type VII collagen, scientists grow the patient's cells in the lab and use a virus-like tool (called a retroviral vector) to give the cells the correct instructions. This allows the cells to make the normal protein that is missing in people with RDEB. The graft is designed to be permanent, and the goal is to improve wound healing by replacing damaged skin cells with healthy ones.

Timeline

Start
2026-01-07
Primary completion
2030-12
Completion
2035-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GMEB-SASS Cell therapy — —